search
Back to results

Gene Therapy for Chinese Hemophilia A (HA)

Primary Purpose

Hemophilia A, Gene Therapy

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Injection of GS001
Sponsored by
Institute of Hematology & Blood Diseases Hospital, China
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hemophilia A

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Be able to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local privacy regulations;
  • Be male and ≥18 years of age;
  • Endogenous FVIII activity levels<1iu. as documented by a certified clinical laboratory at the time of screening.
  • Prior FVIII exposure days (EDs) ≥150 days of any recombinant and/or plasma-derived FVIII protein products based on historical data from the subject's record/history;
  • A. Prophylaxis subjects: have had bleeding events and/or infusions with FVIII protein products during the last 12 weeks documented in the subjects' medical records; B. On-demand subjects: have had ≥4 bleeding events in the last 52 weeks and/or chronic hemophilic arthropathy (pain, joint destruction, and loss of range of motion) in one or more joints;
  • Have no prior history of hypersensitivity or anaphylaxis associated with any FVIII or IV immunoglobulin administration;
  • Have no measurable FVIII inhibitor as assessed by laboratory; or documented no prior history of FVIII inhibitor after 150 EDs (family history of inhibitors will not exclude the subject) and no clinical signs or symptoms of decreased response to FVIII administration;
  • Have acceptable laboratory values:

Hemoglobin ≥11 g/dL; Platelets ≥100,000 cells/μL; Aspartate Transaminase(AST), alanine aminotransferase (ALT), alkaline phosphatase ≤1.25x upper limit of normal at the testing laboratory; Bilirubin ≤1.25x upper limit of normal(ULN); Creatinine ≤2.0 mg/dL.

• Agree to use reliable barrier contraception until three consecutive semen samples after the administration of GS001 are negative for vector sequences.

Exclusion Criteria:

  • HBsAg or hepatitis B core antibody or hepatitis B virus-DNA positivity or hepatitis C virus-RNA viral load positivity. Negative viral assays in two samples, collected at least six months apart, will be required to be considered negative. Both natural clearer and those who have cleared hepatitis C virus on antiviral therapy are eligible;
  • Currently on antiviral therapy for hepatitis B or C;
  • Have significant underlying liver disease, as defined by a preexisting diagnosis of portal hypertension, splenomegaly, encephalopathy, reduction below normal limits of serum albumin or evidence of significant liver fibrosis (fibrosis stage ≥ 3) within the past 6 months prior to or at screening as determined by any of the following diagnostic modalities: AST-to-Platelet Ratio Index (APRI) >1;
  • Have serological evidence of HIV-1 or HIV-2 with CD4 counts ≤200/mm3. Subjects who are HIV-positive and stable, with an adequate CD4 count (>200/mm3) and undetectable viral load (<50 gc/mL) measured twice in the six months prior to enrollment, on an antiretroviral drug regimen are eligible to enroll;
  • Anti-GS001 neutralizing antibody titers ≥1:16, anti-GS001 antibody titers ≥1:400;
  • History of chronic infection or other chronic disease that the Investigator considers to constitute an unacceptable risk;
  • Participated in a previous gene therapy research trial within the last 52 weeks or in a clinical study with an investigational drug within the last 12 weeks;
  • Any concurrent clinically significant major disease or any other condition that, in the opinion of the Investigator, makes the subject unsuitable for participation in the study;
  • Bad compliance.

Sites / Locations

  • Chinese Academy of Medical Science and Blood Disease HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment group

Arm Description

Arm of GS001

Outcomes

Primary Outcome Measures

Incidence of treatment- related adverse events
Number of patients experiencing treatment-related adverse events.
Percentage of subjects in each dose group with newly occurred clinically significant abnormalities in physical examination compared to the baseline.
The number of subjects in each dose group with clinically significant changes in physical examination compared to the baseline.
Changes of Weighted Mean of vital signs (systolic blood pressure [SBP] and diastolic blood pressure [DBP], pulse rate, temperature, respiratory rate) from baseline at each assessment time point for each dose group
The vital signs (SBP, DBP, pulse rate, temperature, respiratory rate) of the subjects were measured. The maximum, minimum, and mean observed values of vital signs (SBP, DBP, pulse rate, temperature, respiratory rate) from the dosing (Day 1) to the end of the study were calculated for each subject.
Changes of Mean Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amio Transferase (AST) from baseline at each assessment time point for each dose group
Blood samples of subjects were collected for the evaluation of liver function throughout this study. All of these parameters are measured to help assess the condition of the liver. For ALP, AST and ALT, the percentage of subjects with the worst post-treatment results in each dose group will be summarized as follows: > 1.0 x ULN ≤ 1.5x ULN; > 1.5 x ULN ≤ 3.0 x ULN; > 3.0 x ULN ≤ 5.0 x ULN; > 5.0 x ULN
Immune response to AAV capsid proteins
Changes in the expression levels of neutralizing and binding antibodies of AAV.
Immune response to FVIII transgene
The changes of FVIII inhibitor and antibody levels
Viral vector shedding of GS001
The vector shedding in serum, PMBC, saliva, urine, semen and feces will be monitored
Thrombosis risk assessment
For any individual who reaches >150% vector-derived FVIII: C activity levels following the infusion of GS001, laboratory parameters of thrombotic potential will be assessed.

Secondary Outcome Measures

Vector- derived FVIII:C and FVIII antigen levels
Vector- derived FVIII:C and FVIII antigen levels will be measured after dosing.
FVIII usage within 1 year after GS001 infusion
Number of FVIII replacement therapies and total utilization of exogenous FVIII (IU/kg) replacement therapy.
Number of bleeding events requiring exogenous FVIII replacement therapy within 1 year after GS001 infusion
Number of bleeding events (Spontaneous and Traumatic) requiring exogenous FVIII replacement therapy
Number of bleeding events within 1 year after GS001 infusion
Number of bleeding events (spontaneous or traumatic) including untreated bleeding events

Full Information

First Posted
January 25, 2021
Last Updated
May 17, 2023
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
search

1. Study Identification

Unique Protocol Identification Number
NCT04728841
Brief Title
Gene Therapy for Chinese Hemophilia A
Acronym
HA
Official Title
Clinical Exploration of Clinical Exploration Adeno-associated Virus Vector Expression of Human Coagulation Factor VIII Gene Therapy for Hemophilia A
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 4, 2021 (Actual)
Primary Completion Date
July 31, 2028 (Anticipated)
Study Completion Date
July 31, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Institute of Hematology & Blood Diseases Hospital, China

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
IHBDH-GTHA-2020 is an open- label, non- randomized study to evaluate the safety, tolerability and kinetics of a single intravenous infusion of GS001 in hemophilia A subjects with <1 IU/dl residual FVIII levels.
Detailed Description
IHBDH-GTHA-2020 is a open- label, non- randomized study to evaluate the safety, tolerability and kinetics of GS001 in hemophilia A subjects with residual FVIII levels<1 IU/dl. The first patient will receive a single intravenous infusion of GS001 at a dose level of 2 x 10^12 vg/kg body weight. After three weeks of follow-up for the first patient post infusion of GS001, the dose of GS001 can be adjusted for the other two patients based on the activity level of FVIII:C and safety assessment. Following completion of the first 3 patients received GS001 infusion at 2 x 10^12 vg/kg dose level , the following 3 patients will continue to be enrolled to this dose group if there isn't any unexpected safety risk based on the assessments of FVIII expression and safety profile. The safety data and the activity level of FVIII:C from the first 6 subjects at 2 x 10^12 vg/kg dose level will undergo review by an independent DMC prior to dosing the first subject in the next dose level, DMC may recommend dose escalation to 6 x 10^12 vg/kg body weight or other recommended dose levels. If the DMC recommends dose escalation to 6 x 10 ^12 vg/kg body weight or other recommended doses, at least 10 weeks of safety data and the activity level of FVIII:C post GS001 infusion from the first 3 subjects in this given dose level will undergo review by an independent DMC prior to dosing the following subjects. Based on the data from the first 3 subjects, DMC may recommend the dose adjustments for subsequent enrolled subjects, and expand the number of subject enrolled. Based on the safety, preliminary efficacy and vector kinetics profile of single intravenous infusions of GS001 at different dose levels in severe hemophilia A patients with endogenous factor FVIII activity levels ≤ 1% in this study, and based on the benefit-risk assessment of the subjects, the dose level to be administered for future larger clinical trial in patients with severe hemophilia A will be determined. After all enrolled subjects have been followed for at least 12 weeks after intravenous infusion GS001, periodic analysis will be performed. Primary analysis of safety and efficacy will be performed 52 (± 2) weeks after intravenous infusion GS001, and all subjects will receive 52 (± 2) weeks of comprehensive safety and efficacy assessments. After completing the 52 (± 2) week visit (end-of-study visit), subjects will continue to be followed in this study for up to an additional 4 years for long-term safety and efficacy assessment to evaluate the long-term safety and efficacy of GS001 treatment. A total of 12 to 15 subjects are expected to be enrolled in this study. Subjects will provide informed consent and then undergo screening assessments up to 4-8 weeks prior administration of GS001. All subjects will undergo 260 weeks (5 years) safety observation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemophilia A, Gene Therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment group
Arm Type
Experimental
Arm Description
Arm of GS001
Intervention Type
Genetic
Intervention Name(s)
Injection of GS001
Intervention Description
Patients will be enrolled sequentially every 3 weeks or more between cohorts. Dose escalation may occur after a single patient has been safely dosed if the resulting FVIII activity at Week 3 is < 5 IU/dL.The dose levels are as follows: 2×10^12 vg/kg 6×10^12vg/kg or other recommended doses 2×10^13 vg/kg or other recommended doses
Primary Outcome Measure Information:
Title
Incidence of treatment- related adverse events
Description
Number of patients experiencing treatment-related adverse events.
Time Frame
From screening through up to the end of study (about 5 years).
Title
Percentage of subjects in each dose group with newly occurred clinically significant abnormalities in physical examination compared to the baseline.
Description
The number of subjects in each dose group with clinically significant changes in physical examination compared to the baseline.
Time Frame
From the start of study treatment (Day 1) through up to the end of study (about 5 years).
Title
Changes of Weighted Mean of vital signs (systolic blood pressure [SBP] and diastolic blood pressure [DBP], pulse rate, temperature, respiratory rate) from baseline at each assessment time point for each dose group
Description
The vital signs (SBP, DBP, pulse rate, temperature, respiratory rate) of the subjects were measured. The maximum, minimum, and mean observed values of vital signs (SBP, DBP, pulse rate, temperature, respiratory rate) from the dosing (Day 1) to the end of the study were calculated for each subject.
Time Frame
From the start of study treatment (Day 1) through up to the end of study (about 5 years).
Title
Changes of Mean Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amio Transferase (AST) from baseline at each assessment time point for each dose group
Description
Blood samples of subjects were collected for the evaluation of liver function throughout this study. All of these parameters are measured to help assess the condition of the liver. For ALP, AST and ALT, the percentage of subjects with the worst post-treatment results in each dose group will be summarized as follows: > 1.0 x ULN ≤ 1.5x ULN; > 1.5 x ULN ≤ 3.0 x ULN; > 3.0 x ULN ≤ 5.0 x ULN; > 5.0 x ULN
Time Frame
From the start of study treatment (Day 1) through up to the end of study (about 5 years).
Title
Immune response to AAV capsid proteins
Description
Changes in the expression levels of neutralizing and binding antibodies of AAV.
Time Frame
From screening period through up to 5 years.
Title
Immune response to FVIII transgene
Description
The changes of FVIII inhibitor and antibody levels
Time Frame
From screening period through up to 5 years.
Title
Viral vector shedding of GS001
Description
The vector shedding in serum, PMBC, saliva, urine, semen and feces will be monitored
Time Frame
From date of infusion until the date of 3 consecutive documented negative results, assessed up to 1 year.
Title
Thrombosis risk assessment
Description
For any individual who reaches >150% vector-derived FVIII: C activity levels following the infusion of GS001, laboratory parameters of thrombotic potential will be assessed.
Time Frame
From the start of study treatment (Day 1) through up to the end of study (about 5 years).
Secondary Outcome Measure Information:
Title
Vector- derived FVIII:C and FVIII antigen levels
Description
Vector- derived FVIII:C and FVIII antigen levels will be measured after dosing.
Time Frame
From pre-dose phase through up to 1 years post-dose
Title
FVIII usage within 1 year after GS001 infusion
Description
Number of FVIII replacement therapies and total utilization of exogenous FVIII (IU/kg) replacement therapy.
Time Frame
From week 3 to week 52 post GS001 infusion.
Title
Number of bleeding events requiring exogenous FVIII replacement therapy within 1 year after GS001 infusion
Description
Number of bleeding events (Spontaneous and Traumatic) requiring exogenous FVIII replacement therapy
Time Frame
Week 3 to Week 52 post GS001 Infusion
Title
Number of bleeding events within 1 year after GS001 infusion
Description
Number of bleeding events (spontaneous or traumatic) including untreated bleeding events
Time Frame
Week 3 to Week 52 post GS001 infusion
Other Pre-specified Outcome Measures:
Title
Long-term FVIII: C activity Level
Description
FVIII: C activity Level at Year 2 (Week 104), Year 3 (Week 156), Year 4 (Week 208), Year 5 (Week 260) post GS001 Infusion
Time Frame
From year 2 to year 5 post GS001 infusion.
Title
Annualized number of bleeding episodesrequiring exogenous FVIII replacement therapy during long-term follow up.
Description
Annualized number of bleeding episodes requiring exogenous FVIII replacement therapy during every one-year period from Years 2 to Year 5 (week 53 to week 260) post GS001 infusion
Time Frame
From year 2 to year 5 post GS001 infusion.
Title
Total utilization of FVIII replacement therapy (IU/kg) per year for long-term follow up.
Description
Total utilization of FVIII replacement therapy (IU/kg) per year from Years 2 to Year 5 (week 53 to week 260) post GS001 infusion
Time Frame
From year 2 to year 5 post GS001 infusion.
Title
Annualized number of bleeding episodes (spontaneous and traumatic) per year for long-term follow up.
Description
Annualized number of bleeding episodes (spontaneous and traumatic) per year including untreated bleeding episodes per year from Years 2 to Year 5 (week 53 to week 260) post GS001 infusion.
Time Frame
From year 2 to year 5 post GS001 infusion.
Title
Target joints
Description
Number of Target joints, International Hemophilia Prevention and Treatment Collaborative Group (IPSG) MRI score, changes in joint health score changes
Time Frame
From date of GS001 infusion until the end of study (about 5 years).
Title
Level of Activity and hemophilia activities list
Description
Changes in Level of Activity and hemophilia activities list
Time Frame
From date of GS001 infusion until the end of study (about 5 years).
Title
Health-related quality of life
Description
Health-related quality of life evaluated by EQ-5D, pain assessment
Time Frame
From date of GS001 infusion until the end of study (about 5 years).
Title
Health economics evaluation
Description
Health economic parameters include, but are not limited to, the following:number of hospitalizations, number of hospitalization days, number of emergency room visits, number of unscheduled visits, number of days off school or work.
Time Frame
From date of GS001 infusion until the end of study (about 5 years).

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Be able to understand the purpose and risks of the study and provide informed consent according to national and local privacy laws; Male subjects and ≥ 18 years of age; Have hemophilia A with ≤1 IU/dL (≤1%) endogenous FVIII activity levels at the time of screening. If the screening result is >1% due to previous treatment with FVIII product, then it may be confirmed by documented historical evidence from a certified clinical laboratory demonstrating ≤1% FVIII activity levels ; Have had ≥150 prior exposure days (EDs) to any recombinant and/or plasma-derived FVIII protein products; Subjects have been on prophylactic exogenous FVIII therapy or on-demand exogenous FVIII therapy in the year prior to screening: Prophylaxis subjects: Have had bleeding events during the last 12 weeks, as documented in the subjects' medical records; or On-demand subjects: ≥ 3 bleeding episodes (spontaneous or traumatic) requiring exogenous FVIII therapy in the past 52 weeks; No history of hypersensitivity or anaphylaxis associated with FVIII product administration; Have no measurable FVII inhibitor as assessed by laboratory two times that were at least one week apart; or documented no prior history of FVIII inhibitor after 150 EDs and no clinical signs or symptoms of decreased response to FVIII infusion ; Have acceptable laboratory values sampled at screening and repeated prior to Day 0; A. Hemoglobin ≥ 11 g/dL; B. Platelets ≥ 100 x 10^9/L; C. AST, ALT, alkaline phosphatase ≤ 1.25 upper limit of normal (ULN); D. Bilirubin ≤ 1.25 ULN; E. Creatinine ≤ 2 mg/dL. Agree to use reliable barrier contraception until the end of the 52 weeks observation period, and three consecutive semen samples are negative for vector sequences after GS001 infusion. Exclusion Criteria: Have Hepatitis B, hepatitis C or HBsAg, HCVAb, HBV-DNA, HCV-RNA are positive and have clinical significance. Both natural clearers and those who have cleared HCV on antiviral therapy are deemed eligible; Currently Receiving antiviral therapy for hepatitis B and C; Have underlying liver disease, as defined by previous diagnosis of portal hypertension, splenomegaly, hepatic encephalopathy, decrease of serum albumin and liver fibrosis ≥ 3 stage; or liver biopsy within the past 6 months confirmed METAVIR ≥ 3, FibroScan > 8.3 kPa, Fibro Test/Fibro SURE > 0.48, APRI > 1; Subject has any confirmed congenital or acquired immunodeficiency diseases (e.g., various common type of immunodeficiency diseases, human immunodeficiency virus [HIV] infection, organ transplantation) ; Have Anti-AAV8 neutralizing antibody titer ≥ 1:16, anti-AAV8 binding antibody titer ≥ 1:400; Have history of chronic infections or other chronic diseases that may pose a risk to the study participation; Have participated in a previous gene therapy research trial within the last 52 weeks or in a clinical study with an investigational drug within the past 30 days; The subject has any concurrent diseases that cannot tolerate treatments of prednisone or prednisolone as judged by the investigator; History of arterial or venous thromboembolic events (e.g., deep vein thrombosis, non-hemorrhagic stroke, pulmonary embolism, myocardial infarction, arterial embolism); Known inherited or acquired thrombophilia, including conditions associated with increased risk of thromboembolism, such as atrial fibrillation; Major surgery planned in 1 year period following the infusion with GS001; Hypersensitivity to the study vector; Have clinically major diseases or any other unspecified conditions that, in the opinion of the Investigator, makes the subject unsuitable for participating in the study; Patients who are unable or unwilling to comply with the schedule of visits and study assessments described in the clinical protocol; Evidence of other bleeding disorders not associated with hemophilia A.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Wei Liu, MD
Phone
+82223909240
Email
liuwei1@ihcams.ac.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Lei Zhang, MD
Phone
+82223909240
Email
zhanglei1@ihcams.ac.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lei Zhang, MD
Organizational Affiliation
Chinese Academy of Medical Science and Blood Disease Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chinese Academy of Medical Science and Blood Disease Hospital
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300020
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shuo Chen, MD
Phone
+862223909240
Email
zhanglei1@ihcams.ac.cn
First Name & Middle Initial & Last Name & Degree
Jun L Liu, MD
Phone
+862223909095
Email
gcp@ihcams.ac.cn

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Gene Therapy for Chinese Hemophilia A

We'll reach out to this number within 24 hrs